The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—marking the first time any mRNA shot has been authorized against a disease other than COVID-19.
"We know from the start that this vaccine has durability, which is important versus the COVID vaccine, [which] can lose efficacy after four to six months, reducing public confidence in the vaccine," Dr. Dan Barouch, director of the Center for Virology and Vaccine Research a...
Vaccine makers are still studying when seniors might need to come back for a booster dose of RSV vaccine in the coming years. They also have yet to decide on a final price, further complicating broader recommendations. GSK said their vaccine could be priced between $200 and $295 per dose, ...
A hypothetical respiratory syncytial virus (RSV) vaccine may be cost effective in the elderly Dutch population who are at high risk of contracting RSV infections. Results of the modelling study showed that it would not be cost effective to vaccinate the entire Dutch population aged ≥ 60 ...
findings coincide with the development of a vaccine for pregnant individuals, while the CDC deliberates on an RSV vaccine for older adults; important given RSV is a leading cause of lower respiratory tract infections in infants and can cause serious illness in both infants and the elderly ...
Papi et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023; 388:595-608. CDC presentation. 21 June 2023. Available at:www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/07-RSV-Adults-Britton-508.pdf ...
) that SARS-CoV-2 and our response to it disturbed the usual RSV season pattern. Now that RSV is a notifiable disease, these data will get better ahead of the widespread use of an RSV vaccine for older adults and soon for children. It will be essential to watch the change in RSV ...
查看详细目录内容或报告样本链接申请:https://www.qyresearch.com.cn/reports/4326352/respiratory-syncytial-virus-vaccine-for-the-elderly 老年人用呼吸道合胞病毒(RSV)疫苗报告主要研究范围有: 第1章:报告统计范围、老年人用呼吸道合胞病毒(RSV)疫苗产品细分及主要的下游市场,行业背景、发展历史、现状及趋势等 ...
In 2022, nirsevimab, the first long-acting monoclonal antibody available for prevention of RSV in a broad infant population was licensed in the European Union and the United States, followed by a vaccine for elderly and maternal immunization in 2023 [24, 25]. In 2024, the German Standing ...
如您需要查看完整版(目录+图表)或申请报告样本可点击链接:https://www.qyresearch.com.cn/reports/4326349/respiratory-syncytial-virus-vaccine-for-the-elderly 老年人用呼吸道合胞病毒(RSV)疫苗报告主要研究企业名单如下,也可根据客户要求增加目标企业:GSK、Pfizer、Moderna、第一三共、Icosavax、Sanofi、蓝湖生物技...